EPO906 Therapy in Patients With Advanced Kidney Cancer

Completed · Phase 2

Conditions studied: Kidney Neoplasms

In brief

This study will examine whether the investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause kidney cancer.

Key facts

Study ID

NCT00035243

Run by

Novartis Pharmaceuticals

People needed

53

Starts

2002-04-01

Last updated by the study team

2012-04-17

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The following patients may be eligible for this study:
• Histologically or cytologically documented evidence of epithelial renal cell carcinoma with at least one measurable lesion (if previous radiation treatment, the target lesion must have demonstrated progression since the radiation)
• Patients must have had a prior nephrectomy
• Must have a life expectancy of greater than three (3) months
• Patients who have had 0-1 prior cytokine treatment regimen (i.e. IL-2, IFN-?) or relapsed less than one year after such treatment may be eligible.

You may not qualify if…

• The following patients are not eligible for this study:
• Patients who have received more than one (1) prior cytokine regimen (i.e. IL-2, IFN?) or relapsed more than one year after receiving such treatment are not eligible
• Patients who have had any prior chemotherapy (including a combination therapy)
• Patients with symptomatic CNS metastases or leptomeningeal involvement
• Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1
• Patients with severe cardiac insufficiency
• Patients taking Coumadin or other warfarin-containing agents with the exception of low dose Coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports
• History of another malignancy within 3 years prior to study entry except curatively treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ
• Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae
• HIV+ patients
• Pregnant or lactating females.

Where it is running

• UCLA Medical Center — Los Angeles, California, United States
• University of Maryland — Baltimore, Maryland, United States
• Wayne State University Karmanos Cancer Center — Detroit, Michigan, United States
• Our Lady Of Mercy Medical Center — The Bronx, New York, United States
• Cleveland Clinic Foundation — Cleveland, Ohio, United States
• University of Washington — Seattle, Washington, United States
• Centre L. Berard — Lyon, France
• Institut Gustave Roussy — Villejuif, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.